Molecular structure of NU 1025, CAS Number: 90417-38-2
NU 1025 (CAS 90417-38-2)
See product citations (9)
Alternate Names:
8-Hydroxy-2-methylquinazoline-4-one
Application:
NU 1025 is a potent PARP-1 and Topo I inhibitor
CAS Number:
90417-38-2
Purity:
>98%
Molecular Weight:
176.2
Molecular Formula:
C9H8N2O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
NU 1025 is a potent PARP-1 (poly(ADP-ribose) polymerase; PARP) inhibitor that has demonstrated the ability to enhance the cytotoxicity of the DNA methylating compound MTIC (sc-211930), bleomycin, and γ-irradiaton. Studies have reported that NU 1025 is 40 to 50 times stronger than benzamide (sc-202494) and 3-aminobenzamide (sc-3501), increases DNA double-strand and single strand breaks, and has neuroprotective effects. Additionally, NU 1025 amplifies the cytotoxic effect of camptothecin (sc-200871), which is a toposimerase I inhibitor.
NU 1025 (CAS 90417-38-2) References
- Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. | Boulton, S., et al. 1999. Carcinogenesis. 20: 199-203. PMID: 10069454
- Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. | Bowman, KJ., et al. 2001. Br J Cancer. 84: 106-12. PMID: 11139322
- Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. | Kaundal, RK., et al. 2006. Life Sci. 79: 2293-302. PMID: 16935310
- Oxidative-induced apoptosis to an immortalized ganglion cell line is caspase independent but involves the activation of poly(ADP-ribose)polymerase and apoptosis-inducing factor. | Li, GY. and Osborne, NN. 2008. Brain Res. 1188: 35-43. PMID: 18053973
- Redundancy between nucleases required for homologous recombination promotes PARP inhibitor resistance in the eukaryotic model organism Dictyostelium. | Kolb, AL., et al. 2017. Nucleic Acids Res. 45: 10056-10067. PMID: 28973445
- Drug-induced xenogenization of tumors: A possible role in the immune control of malignant cell growth in the brain? | Franzese, O., et al. 2018. Pharmacol Res. 131: 1-6. PMID: 29530602
- Identification of hub genes and small-molecule compounds related to intracerebral hemorrhage with bioinformatics analysis. | Liu, Z., et al. 2019. PeerJ. 7: e7782. PMID: 31667013
- HOXB7 acts as an oncogenic biomarker in head and neck squamous cell carcinoma. | Wu, X., et al. 2021. Cancer Cell Int. 21: 393. PMID: 34303375
- Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. | Boulton, S., et al. 1995. Br J Cancer. 72: 849-56. PMID: 7547230
- Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. | Bowman, KJ., et al. 1998. Br J Cancer. 78: 1269-77. PMID: 9823965
Inhibitor of:
4930547N16Rik, PARP, PARP L, PARP-1, PARP-10, PARP-12, PARP-16, PARP-4, PARP-9, Pbx 1, Rad26, Rad9B, RNF146, TIP60, and Topo I.Activator of:
PARG.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NU 1025, 5 mg | sc-203166 | 5 mg | $131.00 |